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ABSTRACT
Phenazines and heterocyclic N-oxides have proven to be interesting classes of antitumoral as well
as antibiotic agents . The natural product myxin (1-hydroxy-6-methoxyphenazine- N5, N10-dioxide)
which belongs to both of these unique classes of molecules, has been found to cause bio-reductively activated, radical-mediated DNA strand cleavage via a de-oxygenative mechanism, making it a potential antitumoral as well as anti-bactierial candidate. In order to investigate as well as improve the bioactive properties of myxin, the following study was designed to synthesize glycosylated myxin analogs. A small catalog of these compounds were synthesized, some of them exhibiting comparable biological activity to that
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1

INTRODUCTION

Phenazines are a class of naturally occurring compounds that are comprised of a nitrogen containing, heterocyclic moiety that vary in both their chemical and physical properties based on the type and
position of substituents present. More than 100 different phenazine structural derivatives have been identified in nature, bacteria being the only source of these natural compounds, and over 6000 compounds that
encompass phenazine as the central moiety have been synthesized.1 Phenazine natural products are isolated as secondary metabolites from bacterial genera such as Pseudomonas, Streptomyces, and other genera
from soil and marine habitats. 2 Both natural and synthetic phenazines have been of particular interest due
to the fact that they have been known to exhibit an extensive range of biological activities including
antitumoral , antibiotic, and anti-parasitic properties.2-3 While the physiological function of naturally occurring phenazines have yet to be fully understood, their mode of action has been proposed to include
biological targets such as polynucleotide interactions, inhibition of topoisomerase I and/or II, and freeradical scavenging.4 The polynucleotide interacting phenomena exhibited by many phenazines such as
pyocyanin(1), iodinin (2), and myxin (3) stems from their planar and aromatic structure which is comparable to known intercalators such as daunomycin, chromomycin, and ethidium bromide.5

Figure 1.1 Phenazines: Pyocyanin (1), Iodinin (2), Myxin (3)

These respective structural characteristics allow for π-π interactions between the phenazines and
the base pairs of DNA, which in turn allows them to intercalate. In addition, phenazines 1,2 and 3 have
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been shown to also bind to either base pairs in double stranded DNA, RNA polymerase, and/or to
ribonucleoside 5’-triphosphate.2 Although, there has yet to be any naturally occurring phenazine that inhibits topoisomerase to date, many synthetic phenazine analogs have been synthesized that have shown
inhibition of topoisomerase I/II.6 This particular strategy consisting of the target of the topoisomerase
enzymes stems from the fact that proliferating cells, like cancer cells contain large concentrations of
topoisomerases.2 Phenazines have also displayed antibiotic activity through radical scavenging phenomena. Certain phenazines such as 1 have been shown to generate radicals that when inside cells, can accept
electrons and thereby interrupt electron transport and respiratory flow in the cell.2
One particular phenazine that has reemerged as a compound of interest due to its antitumoral
properties, and for which the following study is based upon is that of 3 (1-hydroxy-6-methoxyphenazineN5, N10-dioxide, or myxin). Myxin, a natural product, was first isolated from Sorangium sp. By Peterson
et al. in 1966.7 The uniqueness of myxin is of interest due to the fact that it not only belongs to the class
of phenazine compounds, but also to a class known as heterocyclic N-oxides. Heterocyclic N-oxides have
been known to be an attractive class of compounds that exhibit antitumor and antibacterial agency
through their bio-reductively activated, hypoxia-selective DNA-damaging properties.8 Many studies that
have investigated the bio-reductive properties of heterocyclic N-oxides have been based off of a lead
compound known as tirapizamine (TPZ, 4, Figure 1.2), which has been investigated in phase I, II, and III
of clinical trials for the treatment of various cancers.9 The hypoxia-selective cytotoxicity of TPZ and other
compounds in the respective class of compounds lies in its ability to undergo an intracellular one-electron
reduction mechanism (5, Figure 1.2) followed by a deoxygenative mechanism to form a key DNA damaging intermediate (7, Figure 1.2) and other metabolite byproducts (6, Figure 1.2).10 In the presence of
molecular oxygen, the radical intermediate is back oxidized to the parent molecule and does not proceed
through the DNA-damaging intermediate (Figure 1.2).
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Figure 1.2 Bio-reductive Mechanism of Tirapazamine (TPZ)

The use of TPZ in a clinical setting has been limited in the fact that it has exhibited poor extravascular support and thus has lead researchers to investigate similar heterocyclic N-oxides with improved
activity.11 Myxin (3) however, causes bio-reductively activated, radical-mediated DNA strand cleavage
under both aerobic and anaerobic conditions via a deoxygenative mechanism analogous to that characterized for tirapazamine under anaerobic conditions (Figure 1.3).10 This observation has led to biological
activity comparisons drawn between myxin and TPZ that have shown that myxin has comparable activity
to that of TPZ in anaerobic conditions and improved activity in aerobic conditions.10 The fact that myxin
is active under both of these conditions exhibits its potential antibacterial as well as anti-tumoral potential.
It has been suggested that myxin’s aerobically active properties lie within the fact that the radical anion
(8) possesses phenoxyl radical characteristics. This intermediate, which is generated following the enzymatic one electron reduction of myxin (3) has been hypothesized to be more stable and thus less sensitive
to oxygen, which in turn allows the intermediate to proceed through the reductive mechanism and generate DNA damaging radicals.10 Therefore, myxin’s double agency in the phenazine class as well as the
heterocyclic N-oxide class has rendered it as an interesting compound of interest in the fields anticancer
and antibacterial research.
In order to investigate further improvements of the biological activity of myxin along with its
other analogs, the synthesis of glycoside conjugates of myxin analogs was proposed. Carbohydrates car-
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rying an aromatic aglycon have proven to be very important compounds with examples such as antibiotics
such as vancomycin and chromomycin.12 An increase in the understanding of the important roles that
glycoconjugates play in biological processes has led to a demand for these respective compounds in medicinal and pharmacological studies.13 In light of these observations, the synthesis of glycosylated myxin
analogs was carried out in order to investigate the effect that conjugated glycosides had on the bioactivity
of myxin analogs. In addition to the glycosylation of 3, the glycosylation of compound 9 was also of interest due to the fact that previous studies observed that it had significantly lower bioactivity than its precursor, 10 under both aerobic and anaerobic conditions.10 Chowdury et al. suggest that 9 may engage in
redox cycling similar to that of 4, but that the radical anion is incapable of being further reduced allowing
for the release of its own cytotoxic species i.e. the hydroxyl radical.10 However, this “ease of reduction”
of compound 9 may be improved by the addition of acetylated glycosides, which in turn increases the
electrophilic nature of the aromatic system and thus stabilizes the radical anion.14

Figure 1.3 Bio-reductive Mechanism of Myxin

The chemical synthesis of glycosides typically involves the transformation of a particular sugar
into a fully protected glycosyl donor with a leaving group at its anomeric center.13 These leaving groups
can encompass a list of potential functional groups such as halides, acetates, trifluroacetates, and
trichloroacetimidates (Figure 1.4).12
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Figure 1.4 Examples of Acetylated Glucoside Donors

Glycosylation of a suitably protected glycosyl acceptor, which generally contains a free hydroxyl
group, then is carried out. The glycosyl donor can be viewed as “transferring” the glycosyl moiety (which
is generally an electrophile) to the glycosyl acceptor (which is generally a nucleophile). Therefore, the
leaving group as well as the protecting groups are the main fundamental parameters with respect to the
yield and anomeric selectivity of glycosylation reactions.13 However, there are many problems associated
with the glycosylation of phenol groups such as that in compounds such as 3 and 9. Some of these difficulties include the fact that phenols are considered weak nucleophiles, and sensitivity to pH.12 Due to the
stereo-selectivity, ease of use, and strong electrophilic characteristics of glycosyl halides, glycoside bromide was selected as the “donor” and compounds 3 and 9 along with other myxin analogs were selected
as the “acceptors.” This Koenigs- Knorr method encompassed the use of various phase transfer catalysts
under basic conditions, which were utilized in these glycosylation reactions in order to obtain an optimal
yield. Due to the potential improved solubility as well as more positive reduction potential of 9, it was
hypothesized that the myxin analogs such as 9 would exhibit improved bioactivity following their conjugation with different acetylated glycosides.
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2

METHODOLOGY

In the process of chemically synthesizing the central phenazine moiety found in compound 3,
many modifications to the synthetic routes reported by Chowdury et al. were made.10 All synthetic
routes were scaled up to yield larger quantities of the respective product. All materials were purchased at the highest possible purity from Sigma Aldrich Chemical Company. Of the various synthetic routes that could have been carried out in the generation of 3 and its precursors, only the route that
included the cleavage of a single methoxy group in the 1,6-dimethoxy phenazine compound prior to
its oxidation was carried out habitually (Figure 2.1). The glycosylation of 9 was carried out using
modifications to glycosylation techniques described by Wu et al (Figure 2.2).15 In the synthesis of 6methoxyphenazine-1-β-D- glycosides, only the glucose analog of the unacetlayed compound was synthesized. All 1H NMR, 13C NMR, and ESI mass spectra are provided in the appendix.

Figure 2.1 Synthetic Scheme of Myxin
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Figure 2.2 Synthesis of 6-Methoxyphenazine-1-β-D- glycosides

2.1 Synthesis of 1,6-Dimethoxyphenazine

Figure 2.3 Synthesis of 1,6-Dimethoxyphenazine

1,6- Dimethoxyphenazine was synthesized by first adding 0.80 mol (90.22 mL) of o-anisidine to 500
mL of anhydrous benzene. 1.44 mol (176 mL) of o-nitroanisole along with 4 mol (224.42 g) of powdered
potassium hydroxide was then added to the solution. The solution was heated at reflux for 8 hours with
vigorous stirring. Upon cooling overnight, the benzene solution was decanted off and cold water was added to the reaction flask in order to break up the solid and extract any remaining potassium hydroxide. The
solid was then collected via vacuum filtration and washed twice with ethanol. After filtration, the solid
was recrystallized using hot ethanol and dried with an oil pump to yield 14% of product. Rf = 0. 50 (100%
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ethyl acetate) Spectra 1. 13C NMR Spectra 2. Mass spectra (ESI) was also collected in order to verify the
structure Spectra 3.

2.2

Synthesis of 1-Hydroxy-6-methoxyphenazine

Figure 2.4 Synthesis of 1-Hydroxy-6-methoxyphenazine

1-Hydroxy-6-methoxyphenazine was made by adding 0.064 mol (16.21 g) of 1,6
dimethoxyphenazine to 300 mL of dichloromethane in a 500 mL round bottom flask. Then 0.351 mol
(43.46 g) of aluminum chloride was added to the solution under 0˚C condition and allowed to stir for 20
minutes. The progression of the reaction was verified through TLC analysis using 5:1 ethyl acetate to
hexane, Rf = 0.63. The mixture was then worked up by adding solution to 0.5 N HCl in order to quench
the mixture, followed by extraction with dichloromethane. Product was then further purified using silica
gel column chromatography (1:1 ethyl acetate to hexane). Percent yield = 17%. 1HNMR Spectra 4.
13

CNMR Spectra 5. MS (ESI) Spectra 6.

9

2.3 Synthesis of Myxin (1-Hydroxy-6-methoxyphenazine-N5, N10-dioxide)

Figure 2.5 Synthesis of Myxin

To a solution of 0.0044 mol (1.0 g) of 1-Hydroxy-6-methoxyphenazine in 50 mL of dichloromethane was added 3.0 g of m-CPBA. The mixture was stirred at room temperature for 12 hours and
evaluated by TLC using 2:1 hexane to ethyl acetate Rf = 0.63 for compound 3 and 0.45 for compound
9. Mixture was then worked up by diluting with another 100 mL of DCM and washed with 5%
Na2SO3, NaHCO3 and brine washes were then followed by drying with Na2SO4. Products were separated via silica column using 1/3/1 ethyl acetate/hexane/DCM yielding 75% of compound 9 and
5.31% of compound 3. For compound 3, 1H NMR Spectra 7. 13CNMR Spectra 8. Product was also
evaluated using mass spectrometry (ESI) Spectra 9. For compound 9, 1H NMR Spectra 7a.
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2.4 Synthesis of 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide

Figure 2.6 Synthesis of 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide

The synthesis of 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide was carried out by adding 8 mL
of 33% HBr in acetic acid to 1 g (2.60 x 10-3 mol) of β-D-glucose pentaacetate under nitrogen at 0°C. After 5 minutes, the solution was allowed to stir to completion at room temperature (Rf = 0.35 1:1, 1 hexane:
1 ethyl acetate). Upon completion of the reaction, the solution was diluted with 60 mL of dichloromethane and 30 mL of cold H2O. The organic layer was collected and washed with NaHCO3 until the
aqueous layer was at a pH of 7. 90% of product was yielded. 1HNMR Spectra 10. 13CNMR Spectra 11.
MS (ESI) Spectra 12.

2.5 Synthesis of 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide

Figure 2.7 Synthesis of 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide
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The synthesis of 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide was carried out by adding 8
mL of 33% HBr in acetic acid to 1 g (2.60 x 10-3 mol) of β-D-galactose pentaacetate under nitrogen at
0°C. After 5 minutes, the solution was allowed to stir to completion at room temperature (Rf = 0.35 1:1, 1
hexane: 1 ethyl acetate). Upon completion of the reaction, the solution was diluted with 60 mL of dichloromethane and 30 mL of cold H2O. The organic layer was collected and washed with NaHCO3 until
the aqueous layer was at a pH of 7. 87% of product was yielded. 1HNMR Spectra 13. 13CNMR Spectra
14. MS (ESI) Spectra 15.

2.6 Synthesis of 6-Methoxyphenazine-1-β-D-tetraacetylgluco-pyranoside

Figure 2.8 Synthesis of 6-Methoxyphenazine-1-β-D-tetraacetylgluco-pyranoside
113 mg (5.00 x 10-4 mol) of 1-hydroxy-6-methoxyphenazine along with 410 mg of 2,3,4,6-TetraO-acetyl-α-D-galactopyranosyl bromide (1.05 x 10-3mol) was dissolved in 8 mL of CHCl3. 8 mL of
H2O was then added along with 138 mg (1.00 x 10-3 mol) of K2CO3 to the mixture. A catalytic
amount of tertbutylammonium iodide (PTC A)/tertbutylammonium bromide (PTC B)/aliquat 336
(PTC C) was added to the mixture. The reaction was allowed to stir at 50.0° C for 24 hours. The reaction temperature was then decreased to room temperature and the reaction was allowed to stir for an
additional 12 hours. After completion of the reaction, the reaction mixture was worked up by adding
0.1 M HCl and extracting the organic layer. The organic layer was further washed with brine and

12

once again extracted. The final compound was purified via column with 1:1, hexane: ethyl acetate. Rf
= 0.21 using 1:1, hexane: ethyl acetate. Percent yield with PTC A and PTC B was only trace amounts.
Percent yield with PTC C was 75%. 1HNMR Spectra 16. 13CNMR Spectra 17. MS (ESI) Spectra 18.

2.7 Synthesis of 6-methoxyphenazine-N10-oxide-beta-D-tetraacetylgluco-pyranoside

Figure 2.9 Synthesis of 6-methoxyphenazine-N5-oxide-beta-D-tetraacetylgluco-pyranoside

The synthesis of 6-methoxyphenazine-N5-oxide-beta-D-tetraacetylgluco-pyranoside was carried
out by dissolving 50 mg of 6-methoxyphenazine-N5-oxide-beta-D-tetraacetylgluco-pyranoside (8.73
x 10-5 mol) in dichloromethane. 0.106 g of m-CPBA (6.14 x 10-4 mol) was then added to the solution
and the solution was allowed to stir for 24 hours under argon at room temperature. Over the course of
the reaction, the solution gradually turned from yellow to orange. After completion of the reaction,
the organic layer was diluted with dichloromethane and washed with NaHCO3 followed by brine. The
product was purified by column using 1:1, hexane: ethyl acetate. Rf = 0.67 using 100% ethyl acetate.
Yielded 90% of product. 1HNMR Spectra 19. 13CNMR Spectra 20. MS (ESI) Spectra 21.
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2.8 Synthesis of 6-Methoxyphenazine-N5-oxide-1-beta-D-gluco-pyranoside

Figure 2.10 Synthesis of 6-Methoxyphenazine-N5-oxide-1-beta-D-gluco-pyranoside
10 mg (2.47 x 10-5 mol) of 6-Methoxyphenazine-N5-oxide-1-beta-D-gluco-pyranoside was dissolved in a mixture of 6 mL of anhydrous methanol and 1 mL dichloromethane. A small amount sodium methoxide was then added, and the solution was allowed to stir at room temperature for one
hour. After completion of the reaction, Amberlyst 15H form was added to the solution carefully, until
the solution reached a pH of 7. Solution was diluted further with methanol and evaporated. Rf = 0.25
using 10: 1, dichloromethane: methanol. Yielded 99% of product. 1HNMR Spectra 22. 13CNMR
Spectra 23. MS (ESI) Spectra 24.
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2.9 Synthesis of 6-Methoxyphenazine-1-β-D-tetraacetylgalacto-pyranoside

Figure 2.11 6-Methoxyphenazine-1-β-D-tetraacetylgalacto-pyranoside
200 mg (8.84 x 10-4 mol) of 1-hydroxy-6-methoxy phenazine was dissolved in a 8 mL CHCl3/8
mL H2O mixture. 800 mg (2.05 x 10-3 mol) of 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide
was then added to the solution. 276 mg of K2CO3 was then added to the solution followed by a catalytic amount of either PTC A (tetrabutylammonium iodide), PTC B (tetrabutylammonium bromide),
or PTC C (aliquat 336). The solution was allowed to stir under nitrogen for 24 hours at 50°C. After
completion of the reaction, the solution was diluted with 30 mL of dichloromethane. Solution was
then worked up by first adding 30 mL of 0.1 M HCl and then extracting the organic layer. Product
was purified by column using 2:1, hexane: ethyl acetate. Rf = 0.25 using 1:1, hexane: ethyl acetate.
When using both PTC’s A and B, the percent yield was only in trace amounts. PTC C yielded 80%.
1

HNMR Spectra 25. 13CNMR Spectra 26. MS (ESI) Spectra 27.
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2.10

Synthesis of 6-Methoxyphenazine-N5-oxide-beta-D-tetraacetylgalacto-pyranoside

Figure 2.12 6-Methoxyphenazine-N5-oxide-beta-D-tetraacetylgalacto-pyranoside
Dissolved 50 mg (9.00 x 10-5 mol) of 6-methoxyphenazine-1-β-D-tetraacetylgalacto-pyranoside
in 10 mL of dichloromethane. Added 100 mg (5.80 x 10-4) of m-CPBA to the reaction mixture and allowed to stir at room temperature for 24 hours. Over the course of the reaction, the solution turned
from yellow to orange. After completion of the reaction, the organic layer was diluted with dichloromethane and washed with NaHCO3 followed by brine. The product was purified by column using 1:1,
hexane: ethyl acetate. Rf = 0.67 using 100% ethyl acetate. Yielded 90% of product. 1HNMR Spectra
28. 13CNMR Spectra 29. MS (ESI) Spectra 30.

2.11

GI50 Assay

Cancer cell lines HCT-8 (colon cancer cells), HeLa (immortalized cervical cancer cells),
AGS (gastric cancer cells), MCF-7 (breast cancer cells), and HepG2 (liver cancer cells) were
kindly provided by Dr. Jin-Xiong She of Georgia Regents University. The cancer cell line
Molt-4 (acute lymphoblastic leukemia) was kindly provided by Dr. Binghe Wang of Georgia
State University. HCT-8, Hela, AGS and Molt-4 cancer cells were cultured in RPMI 1640
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medium with 10% Fetal Bovine Serum and 1% of the respective drug target. MCF-7 and
HepG2 cancer cells were cultured in DMEM medium with 10% Fetal Bovine Serum and 1%
respective drug target. All cells were incubated in 5% CO2 at 37˚C and were given medium
and plate changes as needed. The evaluation of 50% growth inhibition (GI50) by proliferation assay was carried out by diluting HCT-8, HeLa, and AGS cells to a concentration of 3.5
x 104 cells/mL and MCF-7, Molt-4, and HepG2 cells to a concentration of 4 x 105 cells/ml.
100 µL of the cell suspension was seeded in 96 well plates. The plates were incubated in 5%
CO2 at 37˚C overnight, giving ample time for adherent cell lines to adhere to the plates. The
following day, 1 µL of the prepared compound dilutions (3-fold dilutions) was added to each
well, so that the highest final concentration was 50 µM with 8 successive dilutions. Cells
were then incubated for 72 hours. A Dojindo CCK-8 kit was used to estimate the number of
viable cells in each well according to the manufacturer’s instructions. After 4h incubation,
OD values were measured at 450nm using the multifunctional microplate reader. The data
was then analyzed to construct a GI50 curve and calculate the GI50 value using Sigmaplot
software. Growth inhibition was calculated using the following formula: GI = (control OD–
experimental OD)/control OD.

3

RESULTS AND DISCUSSION

The initial synthesis of compound 3 and its phenazine precursors (3a and 3b) proved successful.
However, synthesizing desirable yields of these respective compounds proved challenging. This can
be attributed to the fact that in each step of this synthesis, the desired compound was a minor product.
An example can be considered compound 3b, which forms 1,6-dihydroxy phenazine as the major
product. The glycosylation of compound 3b proved successful as well. These glycosylation reactions
were carried out using the Koenigs- Knorr method, using K2CO3 as the weak base and various phase
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transfer catalysts to improve the yield of the glycosylation product. In this process, it was determined
that commercially available phase transfer catalyst PTC C gave an optimal yield of 75% of both the
galactoside and glucoside products, while PTC A and PTC B gave minimal yields. Because acetyl
glycoside bromides were utilized as the donor in the glycosylation reactions, only a β- linkage of the
phenazine acceptor was formed, hence the selective capabilities of glycosyl bromides. Oxidation of
the subsequent glycoside phenazines (compounds 10 and compound 13) only yielded mono-oxide
products (compounds 11 and 14). This formation of exclusively mono-oxide products can be attributed to the fact that the presence of the sugar “blocks” the oxidation of the N10 nitrogen by a steric effect. Chowdury et al describes an effect similar to this in previous experiments where the free
hydroxyl group of the 1-hydroxy-6-methoxy phenazine compound was protected with a TBDPS
group. In this study, it was found that the TBDPS group did indeed sterically hinder the oxidation of
the N10 nitrogen and yielded the mono-N5-oxide as a major product.10 In the case where there is no
sugar present, like in the formation of compound 3, previous studies suggest that the hydroxy group
of the 1-hydroxy-6-methoxy phenazine compound directs the oxidation of the N10 nitrogen and thus
yields compound 9 as a major product and compound 3 as a minor product. It also must be noted that
the glycosylation of compound 3 using the Koenigs- Knorr method along with the various phase catalysts proved unsuccessful. One potential reason for this could be the fact that the strength of hydrogen
bond between the phenolic proton and “negatively charged” oxygen is too strong to be cleaved by a
weak base such as K2CO3. Another reason could be simply due to a “steric effect” that arises from the
N10-oxide that disrupts the nucleophilic character of the phenol. The same result was seen when
compound 9 served as the acceptor (which comprised the N10 mono-oxide), in that glycosylation using the Koenigs- Knorr method was unsuccessful (Figure 3.2).
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Figure 3.1 Attempted Glycosylation of 3b, 9, and 3

Nonetheless, a small, initial catalog of novel glycosylated phenazines and heterocyclic N-oxides
was created during these synthetic experiments (Figure 3.2). These compounds were then tested
against various cancer cell lines including HeLa, Skov-3, HCT-8, HepG2, MCF-7, and Molt-4 and assayed in a GI50 study.
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Figure 3.2 Novel Glycosylated Compounds

The GI50 study was carried out under a oxygenated environment meaning that the following compounds were assayed under aerobic conditions. All compounds in the assay were tested at a concentration of 50 µL. For the sake of comparison of the biological activity of compounds 10- 14, doxorubicin (a commercial drug known for its high toxicity by intercalation), and compound 4
(tirapazamine, TPZ) were also included (Table 3.1). Due to the fact that the GI50 assay was carried out
under aerobic conditions, it would be expected that compound 4 would not show any significant
bioactitivty based off the mechanism explained in Figure 1.2. Based off the GI50 values, compounds
11 and 14 exhibited improved bioactivity than compounds 4 and 9 and showed comparable bioactivity with compound 3 when tested with Hela and Skov-3 cell lines. When tested with cell lines HCT-8,
MCF-7, and Molt-4, compounds 11 and 14 exhibited only improved bioactivity than compounds 4
and 9. When the glycosylated compounds that were absent of the N-oxide moiety (compounds 10 and
13) were tested in all cell lines, there was no sign of improved bioactivity in comparison to compounds 3, 4, and 9. It also must be noted that compound 12, which contained the unacetylated
glucoside, N-oxide moiety exhibited no signs of improved bioactivity in comparison to compounds 3,
4, and 9.

OMe
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Possible explanations for the increased activity of compounds 11 and 14 in comparison to 4 and 9
can be attributed to the fact that the presence of the acetylated sugar increases the electrophilic nature
of the overall molecular structure, which in turn increases its reduction potential, stabilizing the radical anion after its reduction. Another explanation of the improved bioactivity of these respective
compounds can be due to the improved uptake of 11 and 14 into the cells due to improved solubility.
However, it must be noted that compound 9 has the N10 oxidized and compounds 11 and 14 have the
N5 oxidized, so direct comparisons cannot necessarily draw an exact conclusion to this difference in
activity. Nonetheless, the comparison of compounds 9 against compounds 11 and 14 can still give
clues into improving the activities of mono-N-oxide phenazines, which have shown significantly less
bioactivity than myxin and tirapazamine overall.10 The lack of improvement in bioactitivty in compounds 10 and 13 against compounds 3, 4, and 9 most likely can be attributed to the lack of the Noxide moiety and thus not allowing for any degree of reduction, which would in turn allow for production of DNA damaging radicals. This result therefore, is in agreement with early hypotheses. Finally, compound 12’s lack of improved bioactivity vs. compound 11 can most likely be attributed to
better uptake of an aceylated glucose as opposed to a free glucose in the structure. It can be predicted
that glucose that is protected with acetyl groups can cross through the cell membranes more readily
than unprotected glucose.
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Table 1 GI50 Assay (µM)

Compound

Hela

Skov3

HCT-8

HepG2

MCF-7

Molt-4

4

52.19

67.94

249.49

89.42

237.72

90.41

Doxorubicin

<0.22

<0.22

3.50

<0.22

0.01

<0.22

3

17.2

12.0

53.83

19.42

31.84

5.08

9

469

125.27

180.63

98.71

308.76

29.16

11

24.19

120.89

>100

>100

195.07

17.79

14

18.79

17.00

96.25

141.85

122.97

17.40

10

>100

>100

>100

>100

>100

17.40

13

>100

>100

>100

>100

>100

21.67

12

>100

>100

>100

>100

>100

33.63

3a

>100

>100

>100

>100

>100

>100

4

CONCLUSION

Although the glycosylation of compounds 3 and 9 were deemed unsuccessful using the KoenigsKnorr method, successful synthesis of glycosylated non-oxidized phenazines using the same method were
indeed successful (10, and 13). Further studies within the glycosylation of heterocyclic-N-oxides will include investigating different glycosylation techniques utilizing other carbohydrate donors such as
glycosyl trichloroacetimidates and thioglycosides. Due to the fact that β-linkaged glycosides were synthesized, future studies will also include the synthesis of α-linkaged glycosides as well. In addition, in order
to further study myxin’s bioactive properties in the field of cancer and antibiotics, functionalization with
various halogen and alkyl groups will also be carried out. The GI50 results of compounds 11 and 14 point
to potential retained biological activity and thus allow for these compounds’ further study within the applicative field of phenazines and heterocyclic- N-oxides. Ongoing studies of these compounds include
many aspects including specific mechanisms of action. In order to study these mechanisms of action, ad-
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ditional assays including DNA cleavage tests (which would give further clues into whether these compounds indeed intercalate, or produce DNA damaging radicals) and assays that would investigate specific
reduction potentials for all synthesized compounds.
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APPENDICES
Appendix A

Spectra 1 1H NMR 1,6-Dimethoxyphenazine
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Spectra 2 13C NMR 1,6-Dimethoxyphenazine
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Spectra 3 Mass Spec (ESI) 1,6-Dimethoxyphenazine
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Spectra 4 1H NMR 1-Hydroxy-6-methoxyphenazine
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Spectra 5 13C NMR 1-Hydroxy-6-methoxyphenazine
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Spectra 6 Mass Spec (ESI) 1-Hydroxy-6-methoxyphenazine
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Spectra 7 1H NMR Myxin
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Spectra 7a 1H NMR 1-Hydroxy-6-Methoxy-N10-Oxide
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Spectra 8 13C NMR Myxin
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Spectra 9 Mass Spec (ESI) Myxin
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Spectra 10 1H NMR 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide
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Spectra 11 13C NMR 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide
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Spectra 12 Mass Spec (ESI) 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide
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Spectra 13 1H NMR 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide
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Spectra 14 13C NMR 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide
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Spectra 15 Mass Spectra (ESI) 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide
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Spectra 16 1H NMR 6-Methoxyphenazine-1-β-D-tetraacetylgluco-pyranoside
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Spectra 17 13C NMR 6-Methoxyphenazine-1-β-D-tetraacetylgluco-pyranoside

42

Spectra 18 Mass Spectra (ESI) 6-Methoxyphenazine-1-β-D-tetraacetylgluco-pyranoside
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Spectra 19 1H NMR 6-Methoxyphenazine-N5-oxide-1-beta-D-tetraacetylgluco-pyranoside

44

Spectra 20 13C NMR 6-Methoxyphenazine-N5-oxide-1-beta-D-tetraacetylgluco-pyranoside
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Spectra 21 Mass Spec (ESI) 6-Methoxyphenazine-N5-oxide-1-beta-D-tetraacetylgluco-pyranoside
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Spectra 22 1H NMR 6-Methoxyphenazine-N5-oxide-1-beta-D-gluco-pyranoside
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Spectra 23 13C NMR 6-Methoxyphenazine-N5-oxide-1-beta-D-gluco-pyranoside
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Spectra 24 Mass Spectra (ESI) 6-Methoxyphenazine-N5-oxide-1-beta-D-gluco-pyranoside
pyranoside
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Spectra 25 1H NMR 6-Methoxyphenazine-1-β-D-tetraacetylgalacto-pyranoside
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Spectra 26 13C NMR 6-Methoxyphenazine-1-β-D-tetraacetylgalacto-pyranoside
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Spectra 27 Mass Spectra (ESI) 6-Methoxyphenazine-1-β-D-tetraacetylgalacto-pyranoside
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Spectra 28 1H NMR 6-Methoxyphenazine-N5-oxide-beta-D-tetraacetylgalacto-pyranoside
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Spectra 29 13C NMR 6-Methoxyphenazine-N5-oxide-beta-D-tetraacetylgalacto-pyranoside
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Spectra 30 Mass Spec (ESI) 6-Methoxyphenazine-N5-oxide-beta-D-tetraacetylgalacto-pyranoside

